title: A retrospective study of the time to clinical endpoints for advanced prostate cancer.
abstract: OBJECTIVE
  To determine the natural history of patients with prostate cancer who start initial androgen-deprivation therapy (ADT) for biochemical failure with no radiographic evidence of disease (D0) or with radiographic metastatic disease (D2), as the history is either not well-defined or is changing, and such data are critical for guiding therapy after prostate cancer recurrence.
  
  
  METHODS
  We retrospectively assessed the time to androgen-independence (AI), defined as the first sustained rise in prostate-specific antigen (PSA) level on ADT, time to metastatic disease and overall survival for 80 patients with metastatic prostate cancer in clinical trials at the National Cancer Institute.
  
  
  RESULTS
  ADT was initiated after metastatic disease in 37 patients and before metastatic disease in 43 patients; in these 43 patients, the median time to developing metastatic disease on ADT was 37.8 months. The median time to AI from the initiation of ADT was 19.3 and 13.1 months in D0 and D2 patients, respectively. The median overall survival from the start of ADT was 89.0 and 63.0 months, and the median overall survival from the time of AI was 63.1 and 44.2 months in D0 and D2 patients, respectively. These 80 patients, which included 43 who had no metastatic disease when starting ADT, had a median survival of 54.8 months after AI prostate cancer.
  
  
  CONCLUSIONS
  We describe the natural history of AI prostate cancer in D0 patients who eventually developed metastasis, and in D2 patients. The results suggest a longer than expected survival with AI prostate cancer, and to our knowledge this is the first study to report the time to metastatic disease for D0 patients from ADT and from AI. These results can be used to help design clinical trials in patients with D0 prostate cancer.
authors.affiliation: Center for Cancer Research, National Cancer Institute/NIH, 10 Center Drive, Bethesda, MD 20892, USA.
authors.forename: Nima
authors.initials: N
authors.lastname: Sharifi
authors.forename: William L
authors.initials: WL
authors.lastname: Dahut
authors.forename: Seth M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
authors.forename: Christopher
authors.initials: C
authors.lastname: Tarassoff
authors.forename: Philip
authors.initials: P
authors.lastname: Arlen
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
mesh_terms: D000328:Adult; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality*; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists